IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.
about
Immunotherapy and gene therapy as novel treatments for cancer.Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer ImmunotherapiesLack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor MicroenvironmentExpression of CD94 by -differentiated NK cells correlates with the and acquisition of cytotoxic features
P2860
IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
IL-12, IL-15, and IL-18 pre-ac ...... leukemia development in vivo.
@en
type
label
IL-12, IL-15, and IL-18 pre-ac ...... leukemia development in vivo.
@en
prefLabel
IL-12, IL-15, and IL-18 pre-ac ...... leukemia development in vivo.
@en
P2093
P2860
P50
P1433
P1476
IL-12, IL-15, and IL-18 pre-ac ...... y leukemia development in vivo
@en
P2093
Aina Ulvmoen
Amanda Sudworth
Anne M Dickinson
Margherita Boieri
Matthew Collin
P2860
P304
P356
10.1080/2162402X.2016.1274478
P577
2017-01-17T00:00:00Z